Cipher receives Health Canada approval of CIP-Fenofibrate

22-Feb-2006

Cipher Pharmaceuticals Inc. announced that it has received final approval from Health Canada for CIP-Fenofibrate, the Company's novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia. Health Canada has issued a Notice of Compliance for CIP-Fenofibrate which allows for the product to be marketed in Canada.

The notification came after the Federal Court of Canada advised the Company it would dismiss the legal proceedings brought by Fournier-Pharma Inc. and Laboratoires Fournier S.A. related to the second of two patent issues. The dismissal cleared the path for Health Canada to issue final approval for CIP-Fenofibrate. Cipher announced in January 2006 that it received final approval for CIP-Fenofibrate in the United States from the U.S. Food and Drug Administration.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances